|
|
Prepublished online as a Blood First Edition Paper on January 30, 2003; DOI 10.1182/blood-2002-10-3188.
 Previous Article | Table of Contents | Next Article 
Blood, 1 June 2003, Vol. 101, No. 11, pp. 4387-4392
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis
Anders Dahm,
Astrid van Hylckama Vlieg,
Bjorn Bendz,
Frits Rosendaal,
Rogier M. Bertina, and
Per Morten Sandset
From the Department of Hematology, Ullevål University Hospital, Oslo, Norway; the Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands; and the Department of Hematology, Leiden University Medical Center, Leiden, Netherlands.
There is now strong experimental evidence that tissue factor pathway inhibitor (TFPI) is a critical inhibitor to modulate tissue factor–induced coagulation, but the role of TFPI as a risk factor for thrombosis is yet to be to be determined. This study investigated the role of low TFPI levels for the development of deep-vein thrombosis (DVT). We determined TFPI activity and TFPI-free and total antigen levels in the subjects enrolled in the Leiden Thrombophilia Study, which is a large population-based case-control study of 474 patients and 474 controls. The odds ratio (OR) for DVT in subjects who had TFPI-free antigen levels below the 10th percentile, as compared with those who had TFPI-free antigen levels above this cutoff, was 1.7 (95% confidence interval [CI], 1.1-2.6). The ORs for low TFPI activity and low total antigen were also mildly increased. When the 5th percentile was used as a cutoff, the ORs were 2.1 (95% CI, 1.1-4.1) for both TFPI-free antigen and TFPI total antigen. Exogenous female hormones had a profound lowering effect on TFPI levels, with lower levels in oral contraceptive users than in premenopausal nonusers, who had lower levels than men and postmenopausal women. These results indicate that low levels of TFPI, especially low TFPI-free and total antigen in plasma, constitute a risk factor for DVT.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
TFPI and venous thrombosis
- Kenneth A. Bauer
Blood 2003 101: 4228-4229.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
C. Duckers, P. Simioni, L. Spiezia, C. Radu, S. Gavasso, J. Rosing, and E. Castoldi
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency
Blood,
November 1, 2008;
112(9):
3615 - 3623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T.B. Crawley and D. A. Lane
The Haemostatic Role of Tissue Factor Pathway Inhibitor
Arterioscler Thromb Vasc Biol,
February 1, 2008;
28(2):
233 - 242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O. Skouby, J. J. Sidelmann, L. Nilas, and J. Jespersen
A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability
Hum. Reprod.,
April 1, 2007;
22(4):
1186 - 1191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. F.S. Negaard, A. L. Eilertsen, A. Dahm, P. O. Iversen, B. Ostenstad, and P. M. Sandset
Decreased Lung Cancer Survival With Hormone-Replacement Therapy: Caused by a Decreased Tissue Factor Pathway Inhibitor Level?
J. Clin. Oncol.,
June 10, 2006;
24(17):
2683 - 2684.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Hackeng, K. M. Sere, G. Tans, and J. Rosing
Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor
PNAS,
February 28, 2006;
103(9):
3106 - 3111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Pinotti, C. Bertolucci, F. Portaluppi, I. Colognesi, E. Frigato, A. Foa, and F. Bernardi
Daily and Circadian Rhythms of Tissue Factor Pathway Inhibitor and Factor VII Activity
Arterioscler Thromb Vasc Biol,
March 1, 2005;
25(3):
646 - 649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E.A. Dahm, T. O. Andersen, F. Rosendaal, and P. M. Sandset
Biological Relevance of a New TFPI Anticoagulant Activity Assay of Full-Length TFPI.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
2982 - 2982.
[Abstract]
|
|
|
|
|
|
|
M. Erman, H. Abali, B. Oran, I. C. Haznedaroglu, H. Canpinar, S. Kirazli, and I. Celik
Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?
Ann. Onc.,
November 1, 2004;
15(11):
1622 - 1626.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin, W. C. Aird, and J. H. Rand
Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome
Hematology,
January 1, 2003;
2003(1):
497 - 519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
